Strategic procurement and international collaboration to improve access to medicines

Bulletin of the World Health Organization

Volumn 95, Issue 10, 2017, Pages 720-722

  Ferrario, Alessandra ^a   Humbert, Tifenn ^b   Kanavos, Panos ^a   Pedersen, Hanne Bak ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR; ESSENTIAL DRUG;

HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH IMPACT ASSESSMENT; HOSPITAL; HUMAN; INTERSECTORAL COLLABORATION; NOTE; PATENT; PATIENT SAFETY; PHYSICIAN; HEALTH CARE DELIVERY; INTERNATIONAL COOPERATION; SUPPLY AND DISTRIBUTION;

DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; QUALITY OF HEALTH CARE;

EID: 85030678402     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.16.187344     Document Type: Note

References (15)

1. Supply annual report 2015. Nordhavn: United Nations Children’s Fund Supply Division; 2016. Available from: https://www.unicef.org/supply/files/UNICEF_Supply_Annual_Report_2015.pdf [cited 2017 Jul 10]
2. WHO procurement strategy. Geneva: World Health Organization; 2015. Available from: http://www.who.int/about/resources_planning/WHO_Procurement_Strategy_April2015.pdf [cited 2017 Jul 10]
3. International language for drug utilization research. Oslo: Norwegian Institute of Public Health; 2017. Available from: https://www.whocc.no [cited 2017 Jul 10]
4. The past year: 15. Copenhagen: Amgros; 2016. Available from: http://www.amgros.dk/media/45727/6066_amg_aarsmagasin_5_uk_web_sider.pdf [cited 2017 Jul 10]
5. Moe L. Nor-Switch: – safe switch to biosimilar. [Internet]. Oslo: Dagens Medisin; 2016. Available from: http://www.dagensmedisin.no/artikler/2016/10/17/nor-switch--safe-switch-to-biosimilar/ [cited 2017 Jul 10]
6. Agreement on trade-related aspects of intellectual property rights. Geneva: World Trade Organization; 1995. Available from: https://www.wto.org/english/docs_e/legal_e/27-trips.pdf [cited 2017 Jul 20]
7. Johnston A, Asmar R, Dahlöf B, Hill K, Jones DA, Jordan J, et al. Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe. Br J Clin Pharmacol. 2011 Nov;72(5):727–30. doi: http://dx.doi.org/10.1111/j.1365-2125.2011.03987.x PMID: 21486316
8. London therapeutic tender implementation: guidance for clinical use. London: HIV i-Base; 2015. Available from: http://i-base.info/wp-content/uploads/2015/01/London-NHSE-guidance-14Jan2015.pdf [cited 2017 Jul 10]
9. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016 05 31;13(5):e1002032. doi: http://dx.doi.org/10.1371/journal.pmed.1002032 PMID: 27243629
10. Ferrario A, Kanavos P, Humbert T, Iwamoto K, Bak-Pedersen H. Challenges and opportunities in improving access to medicines through efficient public procurement in the WHO European Region. Copenhagen: World Health Organization Regional Office for Europe; 2016. Available from: http://www.euro.who.int/en/health-topics/Health-systems/health-technologiesand-medicines/publications/2016/challenges-and-opportunities-inimproving-access-to-medicines-through-efficient-public-procurement-inthe-who-european-region-2016 [cited 2017 Jul 10]
11. Musungu S, Villanueva S, Blasetti R. Utilizing TRIPS flexibilities for public health protection through south-south regional frameworks. Geneva: South Centre; 2004. Available from: http://apps.who.int/medicinedocs/en/d/Js4968e/ [cited 2017 Jul 10]
12. Report of the United Nations Secretary-General’s high-level panel on access to medicines. Promoting innovation and access to health technologies. New York: High-Level Panel on Access to Health Technologies; 2016. Available from: https://static1.squarespace.com/static/562094dee4b0d00c1a3ef761/t/57d9c6ebf5e231b2f02cd3d4/1473890031320/UNSG+HLP+Report+FINA L+12+Sept+2016.pdf [cited 2017 Jul 10].
13. ’t Hoen EFM, Boulet P, Baker BK. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation. J Pharm Policy Pract. 2017 Jun 10;19: doi: http://dx.doi.org/10.1186/s40545-017-0107-9
14. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: World Health Organization Regional Office for Europe; 2015. Available from: http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-newmedicines-TR-PIO-collaboration-research.pdf?ua=1 [cited 2017 Jul 10]
15. Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004. Brussel: Official Journal of the European Communities; 2004. L 157:45–86. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32004L0048&qid=1500032282159&from=en [cited 2017 Jul 10].